These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34204797)

  • 1. Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma Treatment.
    Li HP; Huang CY; Lui KW; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Kuo YC; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Hsieh JC; Chang KP; Lin CY; Wang HM; Chang YS; Hsu CL
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34204797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasopharyngeal carcinoma patient-derived xenograft mouse models reveal potential drugs targeting cell cycle, mTOR, and autophagy pathways.
    Li HP; Huang CY; Lui KW; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Kuo YC; Huang MY; Fan HC; Lin AC; Hsieh CH; Chang KP; Lin CY; Wang HM; Chao M; Liu JS; Chang YS; Hsu CL
    Transl Oncol; 2023 Dec; 38():101785. PubMed ID: 37713975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma.
    Yuan Y; Zhou X; Song J; Qiu X; Li J; Ye L; Meng X; Xia D
    Ann Otol Rhinol Laryngol; 2008 Mar; 117(3):192-200. PubMed ID: 18444479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis.
    Zhang W; Zeng Z; Zhou Y; Xiong W; Fan S; Xiao L; Huang D; Li Z; Li D; Wu M; Li X; Shen S; Wang R; Cao L; Tang K; Li G
    Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):414-28. PubMed ID: 19430707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
    Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
    Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown.
    Huang WC; Hsu RM; Chi LM; Leu YL; Chang YS; Yu JS
    Cancer Lett; 2007 Apr; 248(1):137-46. PubMed ID: 16919867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2.
    Chen S; Youhong T; Tan Y; He Y; Ban Y; Cai J; Li X; Xiong W; Zeng Z; Li G; Yi M; Liu W; Xiang B
    Carcinogenesis; 2020 Jul; 41(6):723-733. PubMed ID: 31665243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
    Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma.
    Feng X; Lin J; Xing S; Liu W; Zhang G
    BMC Cancer; 2017 Jan; 17(1):90. PubMed ID: 28143425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non-cancerous nasopharyngeal tissues.
    Wan XX; Yi H; Qu JQ; He QY; Xiao ZQ
    Oncol Rep; 2015 Nov; 34(5):2585-601. PubMed ID: 26330189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of N-acetylglucosaminyltransferase V enhances the cetuximab-induced radiosensitivity of nasopharyngeal carcinoma cells likely through EGFR N-glycan alterations.
    Huang X; Liu T; Wang Q; Zhu W; Meng H; Guo L; Wei T; Zhang J
    Glycobiology; 2017 Aug; 27(8):713-725. PubMed ID: 28535302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation.
    Lui VW; Yau DM; Cheung CS; Wong SC; Chan AK; Zhou Q; Wong EY; Lau CP; Lam EK; Hui EP; Hong B; Hui CW; Chan AS; Ng PK; Ng YK; Lo KW; Tsang CM; Tsui SK; Tsao SW; Chan AT
    Oncogene; 2011 Mar; 30(13):1518-30. PubMed ID: 21119603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells.
    Sung FL; Poon TC; Hui EP; Ma BB; Liong E; To KF; Huang DP; Chan AT
    In Vivo; 2005; 19(1):237-45. PubMed ID: 15796181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
    Hu WJ; Liu J; Zhong LK; Wang J
    Biomed Pharmacother; 2018 Jun; 102():681-688. PubMed ID: 29604587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EB virus promotes metastatic potential by boosting STIM1-dependent Ca
    Wei J; Ye J; Luo Y; Weng J; He Q; Liu F; Li M; Lin Y; Li Y; Zhang Z; Qu S; Zhang J
    Cancer Lett; 2020 May; 478():122-132. PubMed ID: 32165272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.